Merck exceeded Wall Street expectations with 9% sales growth in the first quarter of 2024 on the strength of its oncology and vaccine products, the company announced in an earnings report Thursday.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,